---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-176864"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2023-06-28T23:59:59+00:00"
generated_at: "2026-06-13T15:39:37.082739+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Taysha reports new TSHA-120 data analysis supports FDA path; TSHA-102 first patient dosed

## Summary
- New TSHA-120 analysis shows 99% probability of slowing disease progression on mFARS and MFM32 Domain 3; FDA meeting expected Q3 2023.
- First adult patient with Rett syndrome dosed with TSHA-102 in REVEAL Phase 1/2 trial; safety/efficacy update expected early Q3 2023.
- CTA submission for TSHA-102 in pediatric Rett patients in UK mid-2023; IND submission to FDA H2 2023.
- Over seven years of safety data support TSHA-120; DPM using natural history data supports external control for regulatory path.

## SEC filing metadata
- accession: 0001193125-23-176864
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2023-06-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312523176864/0001193125-23-176864-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312523176864/d506285d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-176864
- JSON: https://secwatch.observer/filing/0001193125-23-176864.json
- Plain text: https://secwatch.observer/filing/0001193125-23-176864.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.